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ABSTRACT
The World Health Organization announced on 12 March 2020 a global pandemic of the new SARS-CoV-2 coronavirus causing 
COVID-19 disease associated with pneumonia and acute respiratory failure. SARS-CoV-2 has caused so far over 6.66 mil-
lion recorded cases, of which 393,000 ended in death (as of June 1, 2020). Despite the demographic statistics of incidence, 
there is no current recording of cases in the group of pregnant or perinatal women. Changes occurring in the female body 
system during pregnancy also affect and alter the immune system, and as studies based on other viral respiratory infections 
have shown, the population of pregnant women is at risk of having a severe course of the disease. The aim of the study is 
to summarize current reports on the course of COVID-19 disease in a group of pregnant women and the possible impact 
of SARS-CoV-2 on the foetus and vertical transmission, taking into account changes occurring in the woman’s immune 
system during pregnancy. Available advice and recommendations for antenatal and perinatal care of pregnant women 
during the pandemic period are also included.
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INTRODUCTION
The global pandemic of the contagious COVID-19 dis-
ease, caused by the SARS-CoV-2 coronavirus, was announced 
by the World Health Organization (WHO) on March 12, 
2020 as a result of the dynamic development of the epi-
demic in many countries and continents [1]. SARS-CoV-2 has 
caused so far over 6.66 million recorded cases, of which 
393,000 have ended in death (as of 1.06.2020) [2]. The 
SARS-CoV-2 virus is structurally and functionally like the 
SARS virus and other pathogens from the Coronaviridae 
family [3–4].
Susceptibility to SARS-CoV-2 infection is observed in pa-
tients of all ages. However, according to the available studies, 
the full-blown COVID-19 disease develops much more fre-
quently in elderly adults with associated comorbidities [5]. 
Despite the demographic statistics of incidence, there is 
no current recording of cases in the group of pregnant or 
perinatal women. Pregnancy is a special type of physiol-
ogy during which several changes occur not only in the 
hormonal management, but also in the immune system. Ac-
cording to the available studies, the population of pregnant 
women is exposed to a severe course of infectious diseases 
affecting the upper respiratory tract [6–7]. The current state 
of knowledge is insufficient to clearly indicate and describe 
the above-mentioned clinical issue.
The aim of the study is to summarize current reports 
on the course of COVID-19 disease in a group of pregnant 
women and the possible impact of SARS-CoV-2 on the foe-
tus and vertical transmission, taking into account changes 
occurring in the immune system of women during preg-
nancy. The available recommendations and suggestions for 
antenatal and perinatal care of pregnant women during the 
pandemic period are also included.
THE ROLE OF THE IMMUNE SYSTEM  
IN THE PREGNANCY
The immune system undergoes a change during preg-
nancy, outside the implantation site where suppression 
occurs. The response to microorganisms varies depend-
ing on the type of pathogen and stage of pregnancy. The 
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trophoblast and mother’s immune system reach a state of 
agreement where the immune response during pregnancy 
is a combination of the mother’s systemic response and the 
local foetal-placental response. Therefore, the signals from 
the placenta are the ones that alter mother’s immune sys-
tem, and the immune system during pregnancy is focused 
on integrating the actions of placenta, foetus and pregnant 
woman [8].
Caring for the immune system is one of the elements 
of pre-conception, prenatal and perinatal education. There-
fore, important are protective vaccinations before getting 
pregnant as well as proper diet and supplementation during 
pregnancy. Vitamin D3 facilitates the immune adaptation 
necessary to maintain pregnancy. It regulates the concen-
tration of calcium and phosphate in the plasma, affects the 
state of mineralization of mother and foetal bones and alters 
the work of the system, among others immune system [9]. 
Vitamin D3 deficiency may affect up to 50% of pregnant 
women in the first trimester. The new guidelines assume that 
women planning pregnancy and during pregnancy should 
take vitamin D3 supplements, preferably in doses calculated 
based on blood tests. If it is not possible to determine D3 in 
the blood — the use 2000 IU/d is recommended [10]. Dur-
ing lactation, D3 supplementation does not differ from that 
taken during pregnancy - the dose is selected based on the 
vitamin D3 levels in the blood or 2000 IU/d [11–12].
Iron, as an essential microelement in the process of cellular 
respiration, is also responsible for the synthesis of red blood 
cells, DNA synthesis and regulation of the immune system 
function. Anaemia during pregnancy also affects the increased 
risk of preterm delivery and lower foetal birth weight. The de-
mand of a woman’s body during pregnancy is 26–27 mg/day, 
and during the lactation period 20 mg/day [13–14].
VIRAL RESPIRATORY DISEASES  
AND PREGNANCY
Pneumonia resulting from any infectious aetiology is 
an important cause of morbidity and mortality in pregnant 
women. This is the most common non-pregnancy condition 
that occurs during pregnancy. Twenty-five percent of preg-
nant women who develop pneumonia require hospitaliza-
tion in intensive care units and require ventilation support. 
Viral pneumonia has an even higher level of morbidity and 
mortality during pregnancy than bacterial. Maternal physi-
ological changes associated with pregnancy — including 
altered cellular immunity — may increase the susceptibility 
of pregnant women to illnesses [15].
Analysis based on data from SARS and MERS infections 
shows that both these coronaviruses can cause maternal 
death in a small number of cases (risk factors for death dur-
ing pregnancy have not been clarified). Coronaviruses may 
also result in adverse effects on the foetus and infant, includ-
ing IUGR, preterm delivery, miscarriage and perinatal death. 
Unlike some viral infections, especially Ebola and Zika virus, 
the probability of coronavirus intrauterine transmission from 
mother to foetus is low — no cases of SARS or MERS have 
been documented. The novel coronavirus may influence 
obstetric diseases and outcomes depending on gestational 
age, drug effects or other treatment regimens, differences in 
host resistance reactions, occurrence of comorbidities and 
obstetric diseases and other accompanying variables [15].
CLINICAL MANIFESTATIONS AND THE 
COURSE OF COVID-19 DISEASE
According to one recent meta-analysis of the most com-
mon symptoms of COVID-19 disease which can be identified 
in the general population are: fever (87%), cough (58%), 
shortness of breath (38%), myalgia and fatigue (36%). Head-
ache, excessive sputum production, or smell and taste dis-
orders are less common symptoms. Some patients require 
admission to the Intensive Care Unit, of which, according 
to the authors, the risk of death was estimated at 7% [16]. 
Zaigham et al. performed systematic review based on 18 ar-
ticles, covering 108 cases of pregnant women infected with 
SARS-CoV-2. Among the symptoms analysed, high fever 
(68%) and cough (34%) were the most common ones, while 
fatigue (13%) and shortness of breath (12%) were less com-
mon. Three percent of patients required admission to the In-
tensive Care Unit. There were no deaths in pregnant women, 
however one case of neonatal and one case of intrauterine 
death were recorded [17].
The study, which included the largest group of preg-
nant women infected with SARS-CoV-2 at one time, was 
published by Breslin et al. and included 43 women from 
the United States. Only 7% of women were hospitalized for 
COVID-19 symptoms while the others were admitted for 
obstetric reasons. In this group of patients, dry cough (66%) 
was described as the most common symptom followed by 
fever (48%) and muscle pain (39%) [18].
Based on the analysis of the available studies and lit-
erature, it can be concluded that no significant differences 
in clinical symptoms have been described in the pregnant 
women group infected with SARS-CoV-2 in relation to the 
general population [7]. Although, in most of the cases men-
tioned above the course of the disease was mild or even 
asymptomatic, some of them required intensive care and 
mechanical ventilation.
EFFECT OF SARS-COV-2 ON PREGNANCY  
AND DELIVERY
A meta-analysis conducted by Di Mascio et al. [19] on six 
studies which involved 41 pregnant women illustrates regis-
tered pathologies during pregnancy and delivery in patients 
infected with SARS-CoV-2. Premature delivery occurred in 
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41% of patients, and premature rupture of the membranes 
(PROM) was found in 19% of the patients. A significant 
proportion of patients (i.e. 43%) were at risk of foetal intrau-
terine asphyxia (Tab. 1). However, due to the small group 
of respondents and the fact that retrospective case studies 
have been included in the description, certain bias of the 
results obtained should be taken into account.
The available studies show large differences in the 
prevalence of preterm deliveries
Metaanalia Zagiham et al. [17] reports that 92% of COV-
ID-19 gave birth via C-section. Studies carried out by Breslin et 
al. indicate that 44% of deliveries carried out by surgery [18]. 
Despite different percentages, it can be stated that the 
infection of the patient with SARS-CoV-2 is associated with 
an increased rate of giving birth via C-section in comparison 
to the pregnancies of healthy women population.
In regard to SARS reports, there is an increased risk of 
miscarriage concerning infected pregnant women, espe-
cially at the beginning of pregnancy. Unfortunately, the 
available publications provide residual information about 
complications in maintaining pregnancy in the first tri-
mester. Therefore, it cannot be explicitly stated whether 
SARS-CoV-19 infection increases the risk of miscarriage or 
not. However, it should be emphasized that one of the most 
common symptoms of COVID-19 is fever. According to Yin 
et al. hyperthermia may be a teratogenic factor, especially 
at the stage of embryogenesis i.e. early pregnancy [20].
In the publication of Zheijang University School of Medi-
cine, the drugs recommended for pregnant women are lopina-
vir and ritonavir. Chloroquine and favipiravir were forbidden. 
The Table 2 shows the most important drug interactions [21].
Regarding the vertical transmission of SARS-CoV-2 from 
mother to foetus, current studies do not provide reliable 
reports on the eventual possibility of infection. One of the 
first studies conducted on nine neonates shows that there 
is no evidence of intrauterine coronavirus infection (Tab. 3). 
Nine women with laboratory-confirmed COVID-19 (i.e., posi-
tive throat swab samples) participated in the study. Evidence 
of vertical transmission was evaluated by the presence of 
SARS-CoV-2 in samples of amniotic fluid, umbilical cord blood 
and neonatal throat swabs. Samples of breast milk were also 
taken from patients after the first lactation and tested. Nine 
live births were recorded — in the 1st minute Apgar score 
8–9 and 5th minute Apgar score 9–10. Amniotic fluid, umbili-
cal cord blood, neonatal throat swab and milk samples were 
negative [22]. To date, no SARS-CoV-2 virus has been found 
in umbilical cord blood, amniotic fluid or placental tissue [23].
PERINATAL CARE AND BREASTFEEDING
Most authors of the publication agree that the mere 
fact of contracting COVID-19 is not an indication of the 
urgent delivery of pregnancy. It is recommended, if the 
obstetric situation permits, to delay the planned interven-
tion, induction of delivery and adopt a waiting attitude until 
the woman poses an epidemic threat [24–26]. However, 
increased CTG monitoring is recommended due to reported 
cases of foetal well-being disorders [26]. According to the 
recommendations of the Polish Society of Gynecology and 
Obstetrics, each hospital with a Maternity Ward should have 
Table 1. Occurrence of selectes pathologies during pregnancy and 
delivery in patients infected with SARS-CoV-2 [19]
Pathologies n = 41
Premature birth 41%
PROM (premature rupture of the membranes) 19%
Pre-eclampsia 14%
Foetal intrauterine asphyxia 43%
Table 2. The most important drug interactions [21]
Drug name Potential interactions Contraindication in combined medication
Lopinavir/ritonavir
When combined with drugs associated with CYP3A metabolism (e.g., 
statins, immunosuppressors such as tacrolimus, voriconazole), the plasma 
concentration of the combined drug may increase; leading to 153%, 5.9 folds, 
13 folds increase of the AUC of rivaroxaban, atrovastatin, midazolam, 
respectively. Pay attention to clinical symptoms and apply the TDM
Combined use with amiodarone (fatal 
arrhythmia), quetiapine (severe coma), 
simvastati (rhabdomyolysis) is prohibited
Darunavir/cobicistat
When combined with drugs associated with CYP3A and/or 
CYP2D6 metabolism, the plasma concentration of the combined drugs 
may increase. See lopinavir/ ritonavir
See lopinavir/ritonavir
Arbidol It interacts with CYP3A4, UGT1A9 substrates, inhibitors, and inducers –
Fapilavir
① Theophyllinum increases the bioavailability of fapilavir
② It increases the bioavailability of acetaminophen by 1.79 folds
③ Its combination with pyrazinamide increases the plasma uric acid level




Prohibit to combine with the drugs that may 
lead to the prolonged Q-T interval (such as 
moxifloxacin, azithromycin, amiodarone, etc.)
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a separated so-called „Epidemiological emergency room”. 
It is proposed that it should be created on the model of 
existing “Departments of rapid prenatal diagnosis”. Such 
rooms have the conditions to perform ultrasound, CTG and 
examination of the patient maintaining an epidemiological 
regime whether patient’s condition requires hospitalization. 
If pregnancy is endangered, or there are symptoms that 
may threaten pregnancy, it’s necessary to inform the main 
doctor, or if there is no such possibility, go to the closest 
open hospital with obstetrics facilities. In the hospital, after 
TRIAG, if there is no suspicion of infection, every pregnant 
woman will be examined and further treatment will be es-
tablished. If there are infectious symptoms, patient will be 
transferred to the „epidemiological” admission room, where, 
if the pregnancy threat symptoms requiring hospitalization 
are confirmed, the medical team will first have to rule out 
COVID19 infection [27]. Furthermore, according to recom-
mendations to suspend visits to hospitals, an analogous 
procedure should apply to the family births. It is dictated 
by the overarching goal, i.e. ensuring epidemiological safety 
of patients, pregnant and giving birth hospitalized in ma-
ternity hospitals. All actions should be aimed at minimizing 
the possibility of spreading the above mentioned infection 
and minimizing virus transmission in the environment [28]. 
Limited studies in women suffering from COVID-19 or in-
fected with other Coronaviridae (SARS-CoV) did not confirm 
the presence of the virus in human milk. However, it is not 
known for certain whether infection is transmitted through 
breast milk, but given the low rate of respiratory viral trans-
mission through breast milk, the World Health Organization 
(WHO) states that mothers with COVID-19 can breastfeed [29]. 
It is not recommended to routinely isolate healthy 
new-borns from their suspected or COVID-19 mothers. Iso-
lation can only be recommended if the mother’s and/or 
new-born’s health deteriorates and prevents them from 
being in the rooming-in system. Childcare is best entrusted 
to a healthy family member. These rules should be used to 
suppress symptoms in the mother (generally 5–7 days). So 
far, there are no reported cases regarding new-borns con-
tracting Coronavirus through the milk of infected biological 
mothers. Furthermore, there is no evidence in favour of early 
clamping and cutting of the umbilical cord or early washing 
of the new-born [26, 31–33].
Recommendations regarding the participation of the 
neonatal team and clinical factors indicating the need for 
resuscitation remain unchanged, regardless of the status of 
the pregnant woman regarding COVID-19. These guidelines 
were issued on April 24, 2020, they will change as knowl-
edge and experience in the field of COVID-19 treatment 
develops. Due to the varied level of pandemic severity, 
there may be differences in clinical practice in individual 
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from her child should be based on local guidelines. As a rule, 
the child should stay with the mother if her condition al-
lows. If observation is required, it may be conducted by 
midwives. Skin-to-skin contact and breastfeeding is pos-
sible if proper precautions are taken, including strict hand 
hygiene and the use of masks [30].
SUMMARY
The current clinical knowledge does not present sig-
nificant differences in clinical symptoms or the course of 
the disease in the pregnant women’s group in relation to 
the general women’s population and to the similar age. It 
can be assumed that the routine examination of pregnant 
women before planned hospitalization seems to be justified, 
due to the high percentage of asymptomaticity of pregnant 
women with SARS-CoV-2 infection. Based on the current re-
search, patients with confirmed COVID-19 may be included 
in the risk group of preterm delivery, PROM or intrauterine 
infection during pregnancy. The dynamic development of 
the global pandemic emphasizes the need to constantly 
update knowledge and follow the latest recommendations 
to ensure the highest quality of health services and care for 
patients infected with SRARS-CoV-2. 
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